組換えタンパク質市場：製品、サービス、エンドユーザー、機能別-2025-2030年の世界予測

組換えタンパク質市場は、2023年に50億5,000万米ドルと評価され、2024年には58億米ドルに達すると予測され、CAGR 14.51％で成長し、2030年には130億4,000万米ドルに達すると予測されています。

組換えタンパク質は、組換えDNA技術によって生成される人工タンパク質であり、様々な宿主系での新規タンパク質の発現を可能にします。この技術は、タンパク質を大規模かつ高純度で生産する効率性により、治療、診断、研究用途に極めて重要です。組換えタンパク質は、医薬品、ワクチン、生物製剤の開発において、また植物や動物製品の改良のための農業や食品産業において不可欠です。最終用途は、医学研究、臨床診断、バイオテクノロジー研究など多岐にわたります。組換えタンパク質市場は、バイオリアクター設計の進歩、研究開発投資の増加、革新的な治療薬を必要とする慢性疾患の有病率の上昇といった成長要因の影響を受けています。個別化医療やバイオ医薬品の需要拡大、遺伝子治療や再生医療への応用拡大など、ビジネスチャンスは豊富にあります。市場拡大のためには、新興市場の開拓、コスト効率の高い生産技術の活用、戦略的パートナーシップの形成が不可欠です。しかし、市場の成長には、高い生産コスト、複雑な規制状況、知的財産の問題といった課題があります。タンパク質の発現と精製に関わる技術的な複雑さもハードルとなっています。技術革新を推進するためには、発現システムの最適化、保存と輸送のための新規安定化技術の開発、CRISPRベースの技術を利用したタンパク質の機能性強化に焦点を当てた研究が必要です。競合の考察によると、この市場は競争は激しいが急速に進化しており、継続的な技術の進歩と精密医療へのシフトを特徴としています。企業は組換えタンパク質市場で長期的な成功を収めるために、技術動向や規制の変化を常に把握し、ビジネスモデルにおいて持続可能性と倫理的配慮を重視する必要があります。

市場力学：急速に進化する組換えタンパク質市場の主要市場インサイトを公開

組換えタンパク質市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 消費者の個別化医療とタンパク質治療への注目の高まり
  • 老年人口および小児人口における感染症および慢性疾患の高い有病率
  • 生物製剤およびバイオシミラー蛋白質への需要の高まり
• 市場抑制要因
  • 組換えタンパク質の高コストと維持に伴う時間消費に関する懸念
• 市場機会
  • バイオマーカー探索への注目の高まりと組換えタンパク質開発への投資の急増
  • 動物の繁殖、飼料効率、健康における組換えタンパク質の可能性の高まり
• 市場の課題
  • 代替製品の入手可能性と生産におけるいくつかの問題

ポーターの5つの力：組換えタンパク質市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：組換えタンパク質市場における外部からの影響の把握

外部マクロ環境要因は、組換えタンパク質市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析組換えタンパク質市場における競合情勢の把握

組換えタンパク質市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス組換えタンパク質市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、組換えタンパク質市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 消費者の間でパーソナライズ医療とタンパク質療法への注目が高まる
    • 高齢者や子供の間で感染症や慢性疾患の有病率が高い
    • バイオ医薬品およびバイオシミラータンパク質への需要の急増
  • 抑制要因
    • 組換えタンパク質のコストとメンテナンスにかかる時間の問題
  • 機会
    • バイオマーカーの発見への注目が高まり、組み換えタンパク質の開発への投資が急増
    • 動物の繁殖、飼料効率、健康における組み換えタンパク質の潜在的可能性の拡大
  • 課題
    • 代替製品の入手可能性と生産上のいくつかの問題
• 市場セグメンテーション分析
  • 製品：調査目的での接着分子と受容体の重要な使用
  • サービス：発現サービスは、高収量と標的タンパク質特性との適合性に重点を置いています
  • エンドユーザー：製薬会社やバイオ製薬会社における組換えタンパク質の広範な活用
  • 機能：医薬品の発見と開発における組換えタンパク質の潜在的需要
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 組換えタンパク質市場：製品別

• 接着分子と受容体
• 成長因子とケモカイン
• 免疫応答タンパク質
• キナーゼタンパク質
• 膜タンパク質
• 組み換え代謝酵素
• 調節タンパク質
• 構造タンパク質

第7章 組換えタンパク質市場：サービス別

• クローン
• 表現
• 精製

第8章 組換えタンパク質市場：エンドユーザー別

• 学術調査機関
• 契約調査機関および契約製造機関
• 製薬・バイオ医薬品企業

第9章 組換えタンパク質市場：機能別

• 診断
• 医薬品の発見と開発
  • 生物学的製剤
  • 細胞・遺伝子治療
  • ワクチン

第10章 南北アメリカの組換えタンパク質市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の組換えタンパク質市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの組換えタンパク質市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • iToleranceとNorthway Biotechが融合タンパク質の製造契約を締結
  • バイオビアン、フィンランドの製造施設に5,000万ユーロ超を投資
  • フォルティスライフサイエンスがインターナショナルポイントオブケアを買収
  • Curia、CHOZNプラットフォームで細胞株開発サービスを拡大
  • フューチャー・フィールズ、組み換えタンパク質生産のためのショウジョウバエの規模拡大に向け1,120万米ドルを調達
  • メルクのバイオ開発センター拡張、フランス、マルティヤック
  • シェナンドーバイオテクノロジー、cGMPの実践に従って製造されたCTGrade組換えタンパク質の拡張範囲を発表
  • 富士フイルム、組換えタンパク質の大手メーカーであるシェナンドー・バイオテクノロジーを買収
  • サーモフィッシャーサイエンティフィックがペプロテックの買収を完了、組換えタンパク質に参入

企業一覧

• Takara Bio Inc.
• GeoVax Labs, Inc.
• Takeda Pharmaceutical Company Limited
• LenioBio GmbH
• Sino Biological, Inc.
• Sanofi S.A.
• Bio-Rad Laboratories, Inc.
• R&D Systems, Inc. by Bio-Techne Corporation
• Proteos, Inc.
• BPS Bioscience, Inc.
• Proteintech Group, Inc.
• BioLegend, Inc. by PerkinElmer, Inc.
• Thermo Fisher Scientific, Inc.
• Miltenyi Biotec B.V. & Co. KG
• Fortis Life Sciences LLC
• Sartorius AG
• Bristol-Myers Squibb Company
• Creative BioMart Inc.
• Biogen Inc.
• Abnova Corporation
• Hzymes Biotech
• Merck KGaA
• Novartis AG
• Agilent Technologies, Inc.
• Lonza Group AG
• SK bioscience
• Eli Lilly and Company
• Johnson & Johnson Services, Inc.
• Bhat Bio-tech India Private Limited
• GenScript Biotech Corporation
• Marin Biologic Laboratories, Inc.
• Meridian Bioscience, Inc. by SD Biosensor Inc.
• ProMab Biotechnologies, Inc.
• Abcam PLC
• Laurus Labs Limited
• Biologics International Corp
• Croyez Bioscience Co., Ltd.
• Enzo Life Sciences, Inc.
• Selvita S.A.

LIST OF FIGURES

• FIGURE 1. RECOMBINANT PROTEINS MARKET RESEARCH PROCESS
• FIGURE 2. RECOMBINANT PROTEINS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. RECOMBINANT PROTEINS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. RECOMBINANT PROTEINS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. RECOMBINANT PROTEINS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. RECOMBINANT PROTEINS MARKET DYNAMICS
• TABLE 7. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ADHESION MOLECULES & RECEPTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY GROWTH FACTORS & CHEMOKINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY IMMUNE RESPONSE PROTEINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY KINASE PROTEINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY MEMBRANE PROTEINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY RECOMBINANT METABOLIC ENZYMES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGULATORY PROTEINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY STRUCTURAL PROTEINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CLONING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY EXPRESSION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS & CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CELL & GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 47. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 48. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 49. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 51. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 55. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 56. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 61. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 62. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 67. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 68. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 71. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 73. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 74. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 75. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 76. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 78. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 79. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 80. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 81. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 82. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 83. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 86. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 87. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 88. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 91. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 92. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 93. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 96. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 98. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 101. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 102. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 103. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 106. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 107. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 108. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 111. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 112. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 113. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 116. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 117. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 118. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 121. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 123. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 126. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 127. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 128. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 133. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 134. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 137. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 139. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 142. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 143. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 144. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 147. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 148. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 149. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 152. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 153. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 154. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 157. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 158. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 159. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 162. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 163. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 164. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 165. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 166. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 167. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 168. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 169. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 172. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 173. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 174. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 177. NIGERIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 178. NIGERIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 179. NIGERIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 182. NORWAY RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 183. NORWAY RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 184. NORWAY RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 185. POLAND RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 186. POLAND RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 187. POLAND RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 188. POLAND RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 189. POLAND RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 190. QATAR RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 191. QATAR RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 192. QATAR RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 193. QATAR RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 194. QATAR RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 197. RUSSIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 198. RUSSIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 199. RUSSIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 202. SAUDI ARABIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 203. SAUDI ARABIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 204. SAUDI ARABIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 208. SOUTH AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 209. SOUTH AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 212. SPAIN RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 213. SPAIN RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 214. SPAIN RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 217. SWEDEN RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 218. SWEDEN RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 219. SWEDEN RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 222. SWITZERLAND RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 223. SWITZERLAND RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 224. SWITZERLAND RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 227. TURKEY RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 228. TURKEY RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 229. TURKEY RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 232. UNITED ARAB EMIRATES RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 233. UNITED ARAB EMIRATES RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 234. UNITED ARAB EMIRATES RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 238. UNITED KINGDOM RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 239. UNITED KINGDOM RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 240. RECOMBINANT PROTEINS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 241. RECOMBINANT PROTEINS MARKET, FPNV POSITIONING MATRIX, 2023

The Recombinant Proteins Market was valued at USD 5.05 billion in 2023, expected to reach USD 5.80 billion in 2024, and is projected to grow at a CAGR of 14.51%, to USD 13.04 billion by 2030.

Recombinant proteins are engineered proteins that are generated through recombinant DNA technology, enabling the expression of novel proteins in various host systems. This technology is pivotal for therapeutic, diagnostic, and research applications due to its efficiency in producing proteins at a large scale and with high purity. Recombinant proteins are essential in pharmaceuticals for the development of drugs, vaccines, and biologics, as well as in agriculture and food industries for improving plant and animal products. The end-use scope spans medical research, clinical diagnostics, and biotechnological research. The market for recombinant proteins is influenced by growth factors like advancements in bioreactor design, increasing R&D investment, and a rising prevalence of chronic diseases necessitating innovative therapeutics. Opportunities abound in personalized medicine and the growing demand for biopharmaceuticals, as well as expanding applications in gene therapy and regenerative medicine. A vital recommendation is tapping into emerging markets, leveraging cost-efficient production technologies, and forming strategic partnerships for market expansion. However, market growth is challenged by factors such as high production costs, complex regulatory landscapes, and intellectual property issues. The technical complexities involved in protein expression and purification also pose hurdles. To drive innovation, research should focus on optimizing expression systems, developing novel stabilizing techniques for storage and transportation, and utilizing CRISPR-based technologies to enhance protein functionality. Insights suggest a competitive but rapidly evolving market, characterized by continuous technological advancements and a shift towards precision medicine. Companies need to stay abreast of technological trends and regulatory changes, emphasizing sustainability and ethical considerations in their business models to achieve long-term success in the recombinant protein market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Recombinant Proteins Market

The Recombinant Proteins Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising focus on personalized medicine & protein therapeutics in the consumers
  • High prevalence of infectious & chronic diseases among geriatric population and children
  • Surging inclination of demand toward biologics and biosimilars proteins
• Market Restraints
  • Concerns regarding time consumption coupled with high costs & maintenance of recombinant protein
• Market Opportunities
  • Increasing focus on biomarker discovery and surging investments recombinant protein development
  • Growing potential for recombinant protein in animal reproduction, feed efficiency, and health
• Market Challenges
  • Availability of alternative products and several issues in production

Porter's Five Forces: A Strategic Tool for Navigating the Recombinant Proteins Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Recombinant Proteins Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Recombinant Proteins Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Recombinant Proteins Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Recombinant Proteins Market

A detailed market share analysis in the Recombinant Proteins Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Recombinant Proteins Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Recombinant Proteins Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Recombinant Proteins Market, highlighting leading vendors and their innovative profiles. These include Takara Bio Inc., GeoVax Labs, Inc., Takeda Pharmaceutical Company Limited, LenioBio GmbH, Sino Biological, Inc., Sanofi S.A., Bio-Rad Laboratories, Inc., R&D Systems, Inc. by Bio-Techne Corporation, Proteos, Inc., BPS Bioscience, Inc., Proteintech Group, Inc., BioLegend, Inc. by PerkinElmer, Inc., Thermo Fisher Scientific, Inc., Miltenyi Biotec B.V. & Co. KG, Fortis Life Sciences LLC, Sartorius AG, Bristol-Myers Squibb Company, Creative BioMart Inc., Biogen Inc., Abnova Corporation, Hzymes Biotech, Merck KGaA, Novartis AG, Agilent Technologies, Inc., Lonza Group AG, SK bioscience, Eli Lilly and Company, Johnson & Johnson Services, Inc., Bhat Bio-tech India Private Limited, GenScript Biotech Corporation, Marin Biologic Laboratories, Inc., Meridian Bioscience, Inc. by SD Biosensor Inc., ProMab Biotechnologies, Inc., Abcam PLC, Laurus Labs Limited, Biologics International Corp, Croyez Bioscience Co., Ltd., Enzo Life Sciences, Inc., and Selvita S.A..

Market Segmentation & Coverage

This research report categorizes the Recombinant Proteins Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Adhesion Molecules & Receptors, Growth Factors & Chemokines, Immune Response Proteins, Kinase Proteins, Membrane Proteins, Recombinant Metabolic Enzymes, Regulatory Proteins, and Structural Proteins.
• Based on Services, market is studied across Cloning, Expression, and Purification.
• Based on End-User, market is studied across Academic Research Institutes, Contract Research Organizations & Contract Manufacturing Organizations, and Pharmaceutical & Biopharmaceutical Companies.
• Based on Function, market is studied across Diagnostics and Drug Discovery & Development. The Drug Discovery & Development is further studied across Biologics, Cell & Gene Therapy, and Vaccines.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising focus on personalized medicine & protein therapeutics in the consumers
    • 5.1.1.2. High prevalence of infectious & chronic diseases among geriatric population and children
    • 5.1.1.3. Surging inclination of demand toward biologics and biosimilars proteins
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns regarding time consumption coupled with high costs & maintenance of recombinant protein
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing focus on biomarker discovery and surging investments recombinant protein development
    • 5.1.3.2. Growing potential for recombinant protein in animal reproduction, feed efficiency, and health
  • 5.1.4. Challenges
    • 5.1.4.1. Availability of alternative products and several issues in production
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Significant use of adhesion molecules & receptors for research purposes
  • 5.2.2. Services: Expression services focus on high yields and compatibility with target protein characteristics
  • 5.2.3. End-User: Extensive utilization of recombinant proteins in pharmaceutical and biopharmaceutical companies
  • 5.2.4. Function: Potential demand of recombinant proteins for drug discovery & development
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Recombinant Proteins Market, by Product

• 6.1. Introduction
• 6.2. Adhesion Molecules & Receptors
• 6.3. Growth Factors & Chemokines
• 6.4. Immune Response Proteins
• 6.5. Kinase Proteins
• 6.6. Membrane Proteins
• 6.7. Recombinant Metabolic Enzymes
• 6.8. Regulatory Proteins
• 6.9. Structural Proteins

7. Recombinant Proteins Market, by Services

• 7.1. Introduction
• 7.2. Cloning
• 7.3. Expression
• 7.4. Purification

8. Recombinant Proteins Market, by End-User

• 8.1. Introduction
• 8.2. Academic Research Institutes
• 8.3. Contract Research Organizations & Contract Manufacturing Organizations
• 8.4. Pharmaceutical & Biopharmaceutical Companies

9. Recombinant Proteins Market, by Function

• 9.1. Introduction
• 9.2. Diagnostics
• 9.3. Drug Discovery & Development
  • 9.3.1. Biologics
  • 9.3.2. Cell & Gene Therapy
  • 9.3.3. Vaccines

10. Americas Recombinant Proteins Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Recombinant Proteins Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Recombinant Proteins Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. iTolerance and Northway Biotech Form Manufacturing Pact for Fusion Protein
  • 13.3.2. Biovian Invests Over EUR 50M in Manufacturing Facility in Finland
  • 13.3.3. Fortis Life Sciences acquires International Point of Care
  • 13.3.4. Curia Expands Cell Line Development Offering with CHOZN Platform
  • 13.3.5. Future Fields raises USD 11.2 million to scale up fruit flies for recombinant protein production
  • 13.3.6. Merck's Biodevelopment Centre Expansion, Martillac, France
  • 13.3.7. Shenandoah Biotechnology Introduces Expanded Range of CTGrade Recombinant Proteins Manufactured Following cGMP Practices
  • 13.3.8. Fujifilm to Acquire Shenandoah Biotechnology, Leading Manufacturer of Recombinant Proteins
  • 13.3.9. Thermo Fisher Scientific Completes Acquisition of PeproTech, engaged in Recombinant Proteins

Companies Mentioned

• 1. Takara Bio Inc.
• 2. GeoVax Labs, Inc.
• 3. Takeda Pharmaceutical Company Limited
• 4. LenioBio GmbH
• 5. Sino Biological, Inc.
• 6. Sanofi S.A.
• 7. Bio-Rad Laboratories, Inc.
• 8. R&D Systems, Inc. by Bio-Techne Corporation
• 9. Proteos, Inc.
• 10. BPS Bioscience, Inc.
• 11. Proteintech Group, Inc.
• 12. BioLegend, Inc. by PerkinElmer, Inc.
• 13. Thermo Fisher Scientific, Inc.
• 14. Miltenyi Biotec B.V. & Co. KG
• 15. Fortis Life Sciences LLC
• 16. Sartorius AG
• 17. Bristol-Myers Squibb Company
• 18. Creative BioMart Inc.
• 19. Biogen Inc.
• 20. Abnova Corporation
• 21. Hzymes Biotech
• 22. Merck KGaA
• 23. Novartis AG
• 24. Agilent Technologies, Inc.
• 25. Lonza Group AG
• 26. SK bioscience
• 27. Eli Lilly and Company
• 28. Johnson & Johnson Services, Inc.
• 29. Bhat Bio-tech India Private Limited
• 30. GenScript Biotech Corporation
• 31. Marin Biologic Laboratories, Inc.
• 32. Meridian Bioscience, Inc. by SD Biosensor Inc.
• 33. ProMab Biotechnologies, Inc.
• 34. Abcam PLC
• 35. Laurus Labs Limited
• 36. Biologics International Corp
• 37. Croyez Bioscience Co., Ltd.
• 38. Enzo Life Sciences, Inc.
• 39. Selvita S.A.